Phase II Study of induction Carboplatin+Paclitaxel+Bevacizumab combination therapy for stage III Non-Small-Cell Lung Cancer (NSCLC)

Phase II Study of induction Carboplatin+Paclitaxel+Bevacizumab combination therapy for stage III Non-Small-Cell Lung Cancer (NSCLC) - Phase II Study of induction Carboplatin+Paclitaxel+Bevacizumab combination therapy for stage III NSCLC (TCOG1002)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004327

Enrollment

Registered

2010-10-05

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Squamous Non-Small-Cell Lung Cancer

Interventions

CBDCA AUC=6(day1)+ Paclitaxel 200mg/m2(day1)+ Bevacizumab 15mg/kg (day1) q3weeks 2cycles CBDCA AUC=6(day1)+ Paclitaxel 200mg/m2(day1)+ q3weeks 1cycles Surgical operation is performed o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically confirmed non-squamous non-small cell lung cancer(NSCLC) 2)Patients with stage IIIa or IIIb(UICC-7)However,"T3N1"is excluded 3)Patients with measurable lesion(RECIST ver.1.1) 4)Age:20-74years old 5)ECOG PS 0-1 6)Patients without previous treatment for NSCLC 7)If the patient underwent therapy, there should be the following interval between the therapy and the registration -Open biopsy,Treatment of injury->2 weeks -Aspiration biopsy,->1 week 8)Sufficient organ function neutro>=1500/mm3 Plt >=100000/mm3 Hb >=9.0g/dl T-bil <= 1.5mg/dl GOT/GPT <= 99IU/L Cr >= 1.5mg/dl SpO2 >= 95% or PaO2>=70mmHG FEV1.0 >=1.0L PT-INR<=1.5 Proteinuria <=1+ 9)Patients are expected to live over 3 months 10)Written IC

Exclusion criteria

Exclusion criteria: 1)History of active double cancer within 5 years 2)Overt infection 3)History of hemoptysis 4)With great vessel invasion 5)Cavity in tumor 6)Receiving anticoagulant drug(except Aspirin within 324mg/day) 7)Uncontrollable Gastrointestinal ulceration 8)Current or previous(within the last 1 year)history of GI perforation 9)Severe cardiac disease 10)History of Arterial thromboembolism within 1year 11)Interstitial pneumonia or pulmonary fibrosis detectable on X-ray 12)Peripheral neuropathy > Grade2 13)Major surgical procedure 14)With a history of drug sensitivity 15)History of pregnancy or lactation 16)No intention to practice birth control 17)Patients whose participation in the trial is judged to be inappropriate by the attending doctor

Design outcomes

Primary

Measure	Time frame
ORR	—

Secondary

Measure	Time frame
2 year survival rate Complete resection rate RFS DFS PFS pRR Safety	—

Countries

Japan

Contacts

Public ContactTCOG Lung Cancer affairs office

The Tokyo Cooperative Oncology Group Clinical Study Promotion Agency

tcog-lc@tcog.jp03-5401-5020

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026